Ganaxolone for Treatment in Epilepsy

PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
PRE
P1
P2
P3
Edit

Updated: 06/24/2019

Pipeline Type

New Drugs in Development

Phase Of Development

Phase 3

Sponsors and Collaborators

Marinus Pharmaceuticals, Epilepsy Foundation (EF)

Mechanism of Action

Mechanism Description

synthetic analog of endogenous allopregnanolone which modulats GABAa Receptors

Populations Tested In

PCDH19-related epilepsy ages 1 to 17; CDKL5 ages 2 to 21

Other Resources

Special FDA Designation

Nonprofit or Government Support

Nonprofit

Nonprofit or Government Support Description

Epilepsy Foundation - 2005 investment

Previous Presentations

Presented at meetings (latest date) (Pipeline, AEDD; AES, Eilat, etc)
AEDD XV - May 2019

Location of Clinical Trials

N/A

Sign Up for Emails

Stay up to date with the latest epilepsy news, stories from the community, and more.